Skip to main content

Articles

Page 8 of 39

  1. The phase 2 PACE (Ponatinib Ph+ ALL and CML Evaluation) trial of ponatinib showed robust long-term benefit in relapsed Philadelphia chromosome-positive (Ph+) leukemia; arterial occlusive events (AOEs) occurred...

    Authors: James L. Januzzi, Joseph M. Garasic, Scott E. Kasner, Vickie McDonald, Mark C. Petrie, Jonathan Seltzer, Michael Mauro, Kevin Croce, Ellin Berman, Michael Deininger, Andreas Hochhaus, Javier Pinilla-Ibarz, Franck Nicolini, Dong-Wook Kim, Daniel J. DeAngelo, Hagop Kantarjian…
    Citation: Journal of Hematology & Oncology 2022 15:1
    Content type: Research Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2022 15:33

  2. The use of immune checkpoint blockade (ICB) using antibodies against programmed death receptor (PD)-1, PD ligand (PD-L)-1, and cytotoxic T-lymphocyte antigen 4 (CTLA-4) has redefined the therapeutic landscape ...

    Authors: Lingling Zhu, Jiewei Liu, Jiang Chen and Qinghua Zhou
    Citation: Journal of Hematology & Oncology 2021 14:206
    Content type: Review Published on:

  3. Understanding the adjacent liver microenvironment of hepatocellular carcinoma (HCC) with possible metastasis tendency might provide a strategy for risk classification of patients and potential therapies by con...

    Authors: Haotian Liao, Jinpeng Du, Haichuan Wang, Tian Lan, Jiajie Peng, Zhenru Wu, Kefei Yuan and Yong Zeng
    Citation: Journal of Hematology & Oncology 2021 14:205
    Content type: Letter to the Editor Published on:

  4. Resistance to anti-cancer monoclonal antibody (mAb) therapy remains a clinical challenge. Previous work in our laboratory has shown that T cell help in the form of interleukin-2 maintains long-term NK cell via...

    Authors: Zhaoming Wang, Chaobo Yin, Lawrence G. Lum, Andrean Simons and George J. Weiner
    Citation: Journal of Hematology & Oncology 2021 14:204
    Content type: Letter to the Editor Published on:

  5. Unbiased genetic forward screening using retroviral insertional mutagenesis in a genetically engineered mouse model of human multiple myeloma may further our understanding of the genetic pathways that govern n...

    Authors: Fumou Sun, Yan Cheng, Jesse D. Riordan, Adam Dupuy, Wendy Dubois, Michael Pisano, Jing Dong, Beverly Mock, Fenghuang Zhan, Parameswaran Hari and Siegfried Janz
    Citation: Journal of Hematology & Oncology 2021 14:203
    Content type: Letter to the Editor Published on:

  6. Soft tissue sarcoma (STS) is a predominantly fatal rare malignancy with inadequate treatment options. Glycogen synthase kinase 3β (GSK-3β) is an emerging target in human malignancies. Its therapeutic relevance...

    Authors: S. Verbeke, R. Perret, V. Chaire, E. Richard, V. Velasco, F. Giles, L. Cavalcante and A. Italiano
    Citation: Journal of Hematology & Oncology 2021 14:202
    Content type: Letter to the Editor Published on:

  7. Amplifications of oncogenic genes are often considered actionable. However, not all patients respond. Questions have therefore arisen regarding the degree to which amplifications, especially non-focal ones, me...

    Authors: Amélie Boichard, Scott M. Lippman and Razelle Kurzrock
    Citation: Journal of Hematology & Oncology 2021 14:201
    Content type: Letter to the Editor Published on:

  8. Immune checkpoint blockade resistance narrows the efficacy of cancer immunotherapies, but the underlying mechanism remains elusive. Delineating the inherent mechanisms of anti-PD1 resistance is important to im...

    Authors: Jia-Cheng Lu, Peng-Fei Zhang, Xiao-Yong Huang, Xiao-Jun Guo, Chao Gao, Hai-Ying Zeng, Yi-Min Zheng, Si-Wei Wang, Jia-Bin Cai, Qi-Man Sun, Ying-Hong Shi, Jian Zhou, Ai-Wu Ke, Guo-Ming Shi and Jia Fan
    Citation: Journal of Hematology & Oncology 2021 14:200
    Content type: Research Published on:

  9. Although chimeric antigen receptor T cells demonstrated remarkable efficacy in patients with chemo-resistant hematologic malignancies, a significant portion still resist or relapse. This immune evasion may be ...

    Authors: Jean Lemoine, Marco Ruella and Roch Houot
    Citation: Journal of Hematology & Oncology 2021 14:199
    Content type: Review Published on:

  10. STAT proteins represent an important family of evolutionarily conserved transcription factors that play key roles in diverse biological processes, notably including blood and immune cell development and functi...

    Authors: Nagendra Awasthi, Clifford Liongue and Alister C. Ward
    Citation: Journal of Hematology & Oncology 2021 14:198
    Content type: Review Published on:

  11. Cancer will soon become the leading cause of death in every country in the twenty-first century. This study aimed to analyze the mortality and morbidity of 29 types of cancer in 204 countries or regions from 1...

    Authors: Longfei Lin, Zhiyong Li, Lei Yan, Yuling Liu, Hongjun Yang and Hui Li
    Citation: Journal of Hematology & Oncology 2021 14:197
    Content type: Research Published on:

  12. Myeloid-derived suppressor cells (MDSCs) are derived from bone marrow progenitor cells commonly, which is a heterogeneous cell group composed of immature granulocytes, dendritic cells, macrophages and early un...

    Authors: Wei Lu, Fenghua Cao, Lili Feng, Ge Song, Yi Chang, Ying Chu, Zhihong Chen, Bo Shen, Huaxi Xu, Shengjun Wang and Jie Ma
    Citation: Journal of Hematology & Oncology 2021 14:196
    Content type: Letter to the Editor Published on:

  13. The multipotent mesenchymal stem/stromal cells (MSCs), initially discovered from bone marrow in 1976, have been identified in nearly all tissues of human body now. The multipotency of MSCs allows them to give ...

    Authors: Tianxia Lan, Min Luo and Xiawei Wei
    Citation: Journal of Hematology & Oncology 2021 14:195
    Content type: Review Published on:

  14. The main cause of death in colorectal cancer patients is metastasis. Accumulating evidences suggest that circRNA plays pivotal roles in cancer initiation and development. However, the underlying molecular mech...

    Authors: Jiehua He, Ziqiang Chu, Wei Lai, Qiusheng Lan, Yujie Zeng, Daning Lu, Shaowen Jin, Heyang Xu, Pengwei Su, Dong Yin, Zhonghua Chu and Lu Liu
    Citation: Journal of Hematology & Oncology 2021 14:194
    Content type: Research Published on:

  15. Acute myeloid leukemia (AML) is a common malignant heterogeneous hematopoietic disease with very low average 5-year survival rate due to the refractory feature and high rate of relapse. CD123 is highly express...

    Authors: Shilin Xu, Meichen Zhang, Xiaocui Fang, Jie Meng, Haiyan Xing, Doudou Yan, Jian Liu, Yanlian Yang, Tao Wen, Weiqi Zhang, Jianxiang Wang, Chen Wang and Haiyan Xu
    Citation: Journal of Hematology & Oncology 2021 14:193
    Content type: Letter to the Editor Published on:

  16. To our knowledge, there is no clinical data pertaining to COVID-19 outcomes and safety of COVID-19 vaccination in Russian patients with genitourinary (GU) malignancies. Aim of our analysis was to describe the ...

    Authors: Ilya Tsimafeyeu, Maria Volkova, Galina Alekseeva, Maria Berkut, Alexander Nosov, Igor Myslevtsev, Andrey Andrianov, Andrey Semenov, Pavel Borisov, Ruslan Zukov, Vadim Goutnik, Sergey Savchuk, Natalia Dengina and Timur Mitin
    Citation: Journal of Hematology & Oncology 2021 14:192
    Content type: Research Published on:

  17. The outcome of patients affected by high-risk or metastatic neuroblastoma (NB) remains grim, with ≥ 50% of the children experiencing relapse or progression of the disease despite multimodal, intensive treatmen...

    Authors: Nicola Tumino, Gerrit Weber, Francesca Besi, Francesca Del Bufalo, Valentina Bertaina, Paola Paci, Linda Quatrini, Laura Antonucci, Matilde Sinibaldi, Concetta Quintarelli, Enrico Maggi, Biagio De Angelis, Franco Locatelli, Lorenzo Moretta, Paola Vacca and Ignazio Caruana
    Citation: Journal of Hematology & Oncology 2021 14:191
    Content type: Letter to the Editor Published on:

  18. Small-cell lung cancer (SCLC) is a devastating subtype of lung cancer with few therapeutic options. Despite the advent of immunotherapy, platinum-based chemotherapy is still the irreplaceable first-line therap...

    Authors: Zhihui Zhang, Chaoqi Zhang, Zhaoyang Yang, Guochao Zhang, Peng Wu, Yuejun Luo, Qingpeng Zeng, Lide Wang, Qi Xue, Yi Zhang, Nan Sun and Jie He
    Citation: Journal of Hematology & Oncology 2021 14:190
    Content type: Letter to the Editor Published on:

  19. The hypoxic microenvironment is presumed to be a sanctuary for myeloid leukemia cells that causes relapse following chemotherapy, but the underlying mechanism remains elusive. Using a zebrafish xenograft model...

    Authors: Yunxin Zeng, Xinyu Zhang, Dongjun Lin, Xiaohui Feng, Yuye Liu, Zhengwen Fang, Weijian Zhang, Yu Chen, Meng Zhao, Jun Wu and Linjia Jiang
    Citation: Journal of Hematology & Oncology 2021 14:189
    Content type: Letter to the Editor Published on:

  20. Accumulating evidence shows that N6-methyladenine (m6A) modulators contribute to the etiology and progression of colorectal cancer (CRC). However, the exact mechanisms of m6A reader involved in glycolytic metabol...

    Authors: Senxu Lu, Li Han, Xiaoyun Hu, Tong Sun, Dongping Xu, Yalun Li, Qiuchen Chen, Weifan Yao, Miao He, Zhenning Wang, Huizhe Wu and Minjie Wei
    Citation: Journal of Hematology & Oncology 2021 14:188
    Content type: Research Published on:

  21. Complex interactions between the immune system and tumor cells exist throughout the initiation and development of cancer. Although the immune system eliminates malignantly transformed cells in the early stage,...

    Authors: Weina Yu, Qingyang Lei, Li Yang, Guohui Qin, Shasha Liu, Dan Wang, Yu Ping and Yi Zhang
    Citation: Journal of Hematology & Oncology 2021 14:187
    Content type: Review Published on:

  22. Poly ADP-ribose polymerase inhibitors (PARPi) have transformed ovarian cancer (OC) treatment, primarily for tumours deficient in homologous recombination repair. Combining VEGF-signalling inhibitors with PARPi...

    Authors: Francesca Bizzaro, Ilaria Fuso Nerini, Molly A. Taylor, Alessia Anastasia, Massimo Russo, Giovanna Damia, Federica Guffanti, Francesca Guana, Paola Ostano, Lucia Minoli, Maureen M. Hattersley, Stephanie Arnold, Antonio Ramos-Montoya, Stuart C. Williamson, Alessandro Galbiati, Jelena Urosevic…
    Citation: Journal of Hematology & Oncology 2021 14:186
    Content type: Letter to the Editor Published on:

  23. Anemia is a common disease which affects around 40% of children and 30% of reproductive age women and can have major health consequences. The present study reports the global, regional and national burden of a...

    Authors: Saeid Safiri, Ali-Asghar Kolahi, Maryam Noori, Seyed Aria Nejadghaderi, Nahid Karamzad, Nicola Luigi Bragazzi, Mark J. M. Sullman, Morteza Abdollahi, Gary S. Collins, Jay S. Kaufman and Jessica A. Grieger
    Citation: Journal of Hematology & Oncology 2021 14:185
    Content type: Research Published on:

  24. Metastasis occurs in the majority of pancreatic ductal adenocarcinoma (PDAC) patients at diagnosis or following resection. Patients with liver metastasis and those with lung metastasis have significantly diffe...

    Authors: Xingyi Pan, Jiaojiao Zhou, Qian Xiao, Kenji Fujiwara, Mengwen Zhang, Guanglan Mo, Wei Gong and Lei Zheng
    Citation: Journal of Hematology & Oncology 2021 14:184
    Content type: Letter to the Editor Published on:

  25. Antibody-based therapies targeting CD38 are currently used as single agents as well as in combination regimens for multiple myeloma, a malignant plasma cell disorder. In this study, we aimed to develop anti-CD...

    Authors: Elodie Duray, Margaux Lejeune, Frederic Baron, Yves Beguin, Nick Devoogdt, Ahmet Krasniqi, Yoline Lauwers, Yong Juan Zhao, Matthias D’Huyvetter, Mireille Dumoulin and Jo Caers
    Citation: Journal of Hematology & Oncology 2021 14:183
    Content type: Research Published on:

  26. Asparaginase is an important drug to treat childhood haematological malignancies. Data on the association between human leukocyte antigens (HLA) and asparaginase hypersensitivity among Chinese are lacking. We...

    Authors: Gilbert T. Chua, Jaime S. Rosa Duque, Daniel Ka Leung Cheuk, Alex Wing Kwan Leung, Wilfred Hing Sang Wong, Anthony Pak Yin Liu, Pamela P. W. Lee, Shau Yin Ha, Alan Kwok Shing Chiang, Marco Hok Kung Ho, Wai Keung Chu, Yuk Sing Chan, Chun Wing Luk, Alvin Siu Cheung Ling, Mike Yat Wah Kwan, Oscar Kuen Fong Yiu…
    Citation: Journal of Hematology & Oncology 2021 14:182
    Content type: Letter to the Editor Published on:

  27. Gynecological and breast cancers are a group of heterogeneous malignant tumors. Although existing treatment strategies have ameliorated the clinical outcomes of patients, the overall survival rate of advanced ...

    Authors: Tianhan Xu, Sihui Yu, Jiawen Zhang and Sufang Wu
    Citation: Journal of Hematology & Oncology 2021 14:181
    Content type: Review Published on:

  28. Much progress has been made in targeting CD47 for cancer immunotherapy in solid tumors (ST) and hematological malignancies. We summarized the CD47-related clinical research and analyzed the research trend both...

    Authors: Zhongxing Jiang, Hao Sun, Jifeng Yu, Wenzhi Tian and Yongping Song
    Citation: Journal of Hematology & Oncology 2021 14:180
    Content type: Review Published on:

  29. Ibrutinib plus venetoclax, given with an ibrutinib lead-in, has shown encouraging clinical activity in early phase studies in mantle cell lymphoma (MCL). The ongoing phase 3 SYMPATICO study evaluates the safet...

    Authors: Michael Wang, Radhakrishnan Ramchandren, Robert Chen, Lionel Karlin, Geoffrey Chong, Wojciech Jurczak, Ka Lung Wu, Mark Bishton, Graham P. Collins, Paul Eliadis, Frédéric Peyrade, Yihua Lee, Karl Eckert, Jutta K. Neuenburg and Constantine S. Tam
    Citation: Journal of Hematology & Oncology 2021 14:179
    Content type: Rapid communication Published on:

  30. Cancer stem cells (CSCs) are considered as the major cause to tumor initiation, recurrence, metastasis, and drug resistance, driving poor clinical outcomes in patients. Long noncoding RNAs (lncRNAs) have emerg...

    Authors: Shuiqing Liu, Yan Sun, Yixuan Hou, Liping Yang, Xueying Wan, Yilu Qin, Yongcan Liu, Rui Wang, Pengpeng Zhu, Yong Teng and Manran Liu
    Citation: Journal of Hematology & Oncology 2021 14:178
    Content type: Research Published on:

  31. Integrins are the adhesion molecules and transmembrane receptors that consist of α and β subunits. After binding to extracellular matrix components, integrins trigger intracellular signaling and regulate a wid...

    Authors: Jiangling Xiong, Lianlian Yan, Cheng Zou, Kai Wang, Mengjie Chen, Bin Xu, Zhipeng Zhou and Dingxiao Zhang
    Citation: Journal of Hematology & Oncology 2021 14:177
    Content type: Review Published on:

  33. Previous studies on liquid biopsy-based early detection of advanced colorectal adenoma (advCRA) or adenocarcinoma (CRC) were limited by low sensitivity. We performed a prospective study to establish an integra...

    Authors: Xiaoji Ma, Yikuan Chen, Wanxiangfu Tang, Hua Bao, Shaobo Mo, Rui Liu, Shuyu Wu, Hairong Bao, Yaqi Li, Long Zhang, Xue Wu, Sanjun Cai, Yang Shao, Fangqi Liu and Junjie Peng
    Citation: Journal of Hematology & Oncology 2021 14:175
    Content type: Letter to the Editor Published on:

  34. Factors affecting response to SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic stem cell transplantation (allo-HCT) recipients remain to be elucidated.

    Authors: Lorenzo Canti, Stéphanie Humblet-Baron, Isabelle Desombere, Julika Neumann, Pieter Pannus, Leo Heyndrickx, Aurélie Henry, Sophie Servais, Evelyne Willems, Grégory Ehx, Stanislas Goriely, Laurence Seidel, Johan Michiels, Betty Willems, Adrian Liston, Kevin K. Ariën…
    Citation: Journal of Hematology & Oncology 2021 14:174
    Content type: Research Published on:

  35. In recent years, neutrophils have attracted increasing attention because of their cancer-promoting effects. An elevated neutrophil-to-lymphocyte ratio is considered a prognostic indicator for patients with can...

    Authors: Shumin Xiong, Liaoliao Dong and Lin Cheng
    Citation: Journal of Hematology & Oncology 2021 14:173
    Content type: Review Published on:

  36. Thromboembolism has been reported as a consequence of severe COVID-19. Although warfarin is a commonly used anticoagulant, it acts by antagonising vitamin K, which is low in patients with severe COVID-19. To d...

    Authors: Angel Y. S. Wong, Laurie A. Tomlinson, Jeremy P. Brown, William Elson, Alex J. Walker, Anna Schultze, Caroline E. Morton, David Evans, Peter Inglesby, Brian MacKenna, Krishnan Bhaskaran, Christopher T. Rentsch, Emma Powell, Elizabeth Williamson, Richard Croker, Seb Bacon…
    Citation: Journal of Hematology & Oncology 2021 14:172
    Content type: Research Published on:

  37. GTPase-activating protein (GAP) is a negative regulator of GTPase protein that is thought to promote the conversion of the active GTPase-GTP form to the GTPase-GDP form. Based on its ability to regulate GTPase...

    Authors: Hua He, Jingjing Huang, Sufang Wu, Shiyao Jiang, Lu Liang, Yueying Liu, Wenbing Liu, Li Xie, Yongguang Tao, Yiqun Jiang and Li Cong
    Citation: Journal of Hematology & Oncology 2021 14:171
    Content type: Review Published on:

  38. Lineage plasticity, the ability to transdifferentiate among distinct phenotypic identities, facilitates therapeutic resistance in cancer. In lung adenocarcinomas (LUADs), this phenomenon includes small cell an...

    Authors: Alvaro Quintanal-Villalonga, Hirokazu Taniguchi, Yingqian A. Zhan, Maysun M. Hasan, Shweta S. Chavan, Fanli Meng, Fathema Uddin, Viola Allaj, Parvathy Manoj, Nisargbhai S. Shah, Joseph M. Chan, Metamia Ciampricotti, Andrew Chow, Michael Offin, Jordana Ray-Kirton, Jacklynn D. Egger…
    Citation: Journal of Hematology & Oncology 2021 14:170
    Content type: Research Published on:

  39. Altered metabolic patterns in tumor cells not only meet their own growth requirements but also shape an immunosuppressive microenvironment through multiple mechanisms. Noncoding RNAs constitute approximately 6...

    Authors: Yiyin Zhang, Qijiang Mao, Qiming Xia, Jiaxi Cheng, Zhengze Huang, Yirun Li, Peng Chen, Jing Yang, Xiaoxiao Fan, Yuelong Liang and Hui Lin
    Citation: Journal of Hematology & Oncology 2021 14:169
    Content type: Review Published on:

  40. Patients with hematological malignancies (HM) are at high risk of mortality from SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse outcomes may improve clinical management ...

    Authors: Livio Pagano, Jon Salmanton-García, Francesco Marchesi, Alessandro Busca, Paolo Corradini, Martin Hoenigl, Nikolai Klimko, Philipp Koehler, Antonio Pagliuca, Francesco Passamonti, Luisa Verga, Benjamin Víšek, Osman Ilhan, Gianpaolo Nadali, Barbora Weinbergerová, Raúl Córdoba-Mascuñano…
    Citation: Journal of Hematology & Oncology 2021 14:168
    Content type: Research Published on:

  41. Mantle cell lymphoma (MCL) is a mature B-cell neoplasm with a high initial response rate followed almost invariably by relapse. Here we report the pooled data from 2 studies, BGB-3111-AU-003 and BGB-3111-206, ...

    Authors: Keshu Zhou, Dehui Zou, Jianfeng Zhou, Jianda Hu, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Jie Jin, Fangfang Lv, Ru Feng, Sujun Gao, Daobin Zhou, Constantine S. Tam, David Simpson, Michael Wang…
    Citation: Journal of Hematology & Oncology 2021 14:167
    Content type: Letter to the Editor Published on:

  42. Patients with multiple myeloma are at high risk of severe forms of COVID-19. Despite data showing diminished response to vaccine, the era of highly efficient mRNA vaccine might be a gamechanger. We sought to e...

    Authors: Samuel Bitoun, Julien Henry, Christelle Vauloup-Fellous, Nicolas Dib, Rakiba Belkhir, Lina Mouna, Candie Joly, Delphine Desjardins, Marie Bitu, Roger Le Grand, Raphaèle Seror, Anne-Marie Roque Afonso and Xavier Mariette
    Citation: Journal of Hematology & Oncology 2021 14:166
    Content type: Letter to the Editor Published on:

  43. Although adjuvant transcatheter arterial chemoembolization (TACE) for resected hepatocellular carcinoma (HCC) may improve survival for some patients, identifying which patients can benefit remains challenging....

    Authors: Lei Liang, Chao Li, Ming-Da Wang, Hong Wang, Ya-Hao Zhou, Yong-Yi Zeng, Wan-Guang Zhang, Ting-Hao Chen, Nan-Ya Wang, Jie Li, Yao-Ming Zhang, Yu Wang, Wei-Min Gu, Hao Xing, Yong-Kang Diao, Wan Yee Lau…
    Citation: Journal of Hematology & Oncology 2021 14:165
    Content type: Letter to the Editor Published on:

  44. Peritoneal dissemination (PD) is a major type of gastric cancer (GC) recurrence and leads to rapid death. Current approaches cannot precisely determine which patients are at high risk of PD to provide early in...

    Authors: Dongbing Zhao, Pinli Yue, Tongbo Wang, Pei Wang, Qianqian Song, Jingjing Wang and Yuchen Jiao
    Citation: Journal of Hematology & Oncology 2021 14:164
    Content type: Letter to the Editor Published on:

  45. Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) currently constitutes the leading and overwhelming health issue worldwide. In comparison with adults, ...

    Authors: Jadwiga Węcławek-Tompol, Zuzanna Zakrzewska, Olga Gryniewicz-Kwiatkowska, Filip Pierlejewski, Ewa Bień, Agnieszka Zaucha-Prażmo, Olga Zając-Spychała, Anna Szmydki-Baran, Agnieszka Mizia-Malarz, Wioletta Bal, Małgorzata Sawicka-Żukowska, Agnieszka Kruk, Tomasz Ociepa, Anna Raciborska, Agnieszka Książek, Tomasz Szczepański…
    Citation: Journal of Hematology & Oncology 2021 14:163
    Content type: Research Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2022 15:71

  46. CAR T cell therapy has shown dramatic clinical success in relapsed or refractory B-ALL and other hematological malignancies. However, the loss of specific antigens, cell fratricide, T cell aplasia, and normal ...

    Authors: Jiangzhou Shi, Zijian Zhang, Hong Cen, Han Wu, Shangkun Zhang, Jiaxing Liu, Yingqi Leng, Anqi Ren, Xiyu Liu, Zhijie Zhang, Xiqin Tong, Jinjue Liang, Zhe Li, Fuling Zhou, Liang Huang, You Qin…
    Citation: Journal of Hematology & Oncology 2021 14:162
    Content type: Letter to the Editor Published on:

  47. BCMA-specific chimeric antigen receptor-T cells (CAR-Ts) have exhibited remarkable efficacy in refractory or relapsed multiple myeloma (RRMM); however, primary resistance and relapse exist with single-target i...

    Authors: Heng Mei, Chenggong Li, Huiwen Jiang, Xinying Zhao, Zhiping Huang, Dan Jin, Tao Guo, Haiming Kou, Lin Liu, Lu Tang, Ping Yin, Zhihui Wang, Lisha Ai, Sha Ke, Yimeng Xia, Jun Deng…
    Citation: Journal of Hematology & Oncology 2021 14:161
    Content type: Research Published on:

  48. In this era of precision medicine, with the help of biomarkers, immunotherapy has significantly improved prognosis of many patients with malignant tumor. Deficient mismatch repair (dMMR)/microsatellite instabi...

    Authors: Wantao Wu, Yihan Liu, Shan Zeng, Ying Han and Hong Shen
    Citation: Journal of Hematology & Oncology 2021 14:160
    Content type: Review Published on:

  49. New targeted antibody–drug conjugates (ADCs) against multiple myeloma are known to induce adverse effects that may lead to treatment discontinuation. Preclinical studies reported early severe ocular damage rel...

    Authors: Kevin Marquant, Anne Quinquenel, Carl Arndt and Alexandre Denoyer
    Citation: Journal of Hematology & Oncology 2021 14:159
    Content type: Case report Published on:

  50. Authors: Zhaojin Yu, Wensi Liu, Ying He, Mingli Sun, Jiankun Yu, Xue Jiao, Qiang Han, Haichao Tang, Bing Zhang, Yunkai Xian, Jing Qi, Jing Gong, Wang Xin, Gang Shi, Fengping Shan, Rui Zhang…
    Citation: Journal of Hematology & Oncology 2021 14:158
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2021 14:71

JHO logo
Submit manuscript

Follow

Annual Journal Metrics

  • 2022 Citation Impact
    28.5 - 2-year Impact Factor
    23.1 - 5-year Impact Factor
    4.045 - SNIP (Source Normalized Impact per Paper)
    6.046 - SJR (SCImago Journal Rank)

    2023 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    59 days submission to accept (Median)

    2023 Usage 
    3,173,795 downloads
    2,671 Altmetric mentions

On the blog

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us